- Joined
- Jul 16, 2019
- Messages
- 303
- Reaction score
- 569
As mentioned in another thread, multiple case reports and animal studies are showing a benefit to relatively low dose RT in Alzheimer's dz. Sometimes amyloid plaques are disappearing and memory is improving (animals), and sometimes memory is improving without a change in amyloid burden. Earlier in the disease is thought to be more beneficial time to intervene than late/advanced stages.
There is an interesting case report from a woman in Michigan on hospice for Alzheimer's who got 5 CT scans to the brain and went from essentially mute and wheelchair-bound to interacting with people again:
There is now an FDA-approved diagnostic test, Lumipulse, that detects the abnormal amyloid isoform 42 in the CSF. Having a biomarker (like PSA) is really important for making progress with a disease, but the jury is still out if reducing a surrogate like amyloid is enough to justify a therapy, as shown by the controversial Aduhelm FDA approval. It didn't help that Biogen wanted to charge $56,000 for a year of anti-amyloid monoclonal Ab. Lumipulse may be able to eliminate the need for some brain imaging at diagnosis but does require a lumbar puncture:
www.fda.gov
Nobody seems sure how the radiation may be helping, but immuno-modulation may be part of it because microglia levels (brain macrophages) and polarization (M1 to M2) change after XRT, sort of how low-dose XRT changes the tumor microenvironment in Radscopal.
www.mdpi.com
Any interest in a trial?
There is an interesting case report from a woman in Michigan on hospice for Alzheimer's who got 5 CT scans to the brain and went from essentially mute and wheelchair-bound to interacting with people again:
There is now an FDA-approved diagnostic test, Lumipulse, that detects the abnormal amyloid isoform 42 in the CSF. Having a biomarker (like PSA) is really important for making progress with a disease, but the jury is still out if reducing a surrogate like amyloid is enough to justify a therapy, as shown by the controversial Aduhelm FDA approval. It didn't help that Biogen wanted to charge $56,000 for a year of anti-amyloid monoclonal Ab. Lumipulse may be able to eliminate the need for some brain imaging at diagnosis but does require a lumbar puncture:
FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
FDA today permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.
Nobody seems sure how the radiation may be helping, but immuno-modulation may be part of it because microglia levels (brain macrophages) and polarization (M1 to M2) change after XRT, sort of how low-dose XRT changes the tumor microenvironment in Radscopal.
Low-Dose Ionizing Radiation Modulates Microglia Phenotypes in the Models of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common type of dementia. AD involves major pathologies such as amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain. During the progression of AD, microglia can be polarized from anti-inflammatory M2 to pro-inflammatory M1 phenotype. The activation...
www.mdpi.com
Any interest in a trial?
